他汀类药物对高LDL-C血症伴房颤患者血清hs-CRP的影响被引量：1

Effect of Statin Therapy on Serum hs-CRP Level of Patients with High LDL-C in Atrial Fibrillation

下载PDF

导出

摘要目的:探讨他汀类药物对高LDL-C血症伴心房颤动患者血清hs-CRP的影响及临床意义。方法:以高LDL-C血症伴房颤的114例患者作为房颤组,高LDL-C血症窦性心律的55例患者为窦律组,根据是否使用他汀类药物治疗分成窦律非治疗组27例、窦律治疗组28例、房颤非治疗组55例和房颤治疗组59例,比较各组血清hs-CRP。结果:房颤非治疗组血清hs-CRP显著高于窦律非治疗组(P<0.05);窦律组内血清hs-CRP差异无统计学意义(P>0.05);房颤治疗组血清hs-CRP明显低于房颤非治疗组(P<0.05)。结论:高LDL-C血症伴房颤患者血清hs-CRP升高,他汀类药物治疗可降低高LDL-C血症伴房颤患者血清hs-CRP水平。 Objective：To study the effect of statin therapy on serum hs-CRP level of patients with high LDL-C in atrial fibrillation（AF） and its clinical significance. Methods： 114 high LDL-C patients with AF were classified as AF group, 55 high LDL-C patients with sinus rhythm （SR） were classified as SR group, and they were divided into SR with statin therapy group （n=27） and SR without statin therapy group （n=28）, AF without statin therapy group （n=55） and AF with statin therapy group （n=59） according to with or without statin therapy. The levels of serum hs-CRP were compared among the groups. Results： The serum hs-CRP level in AF without statin therapy group was significantly higher than that of the SR without statin therapy group （P〈0.05）,and the serum hs-CRP level in SR patients did not reveal any significant differences between with and without statin therapy （P〉0.05）. The serum hs-CRP level in AF with statin therapy group was significantly lower than that in AF without statin therapy group （P〈0.05）. Conclusions：The findings of this study suggest that statin may be very effective in decreasing serum levels of hs-CRP in high LDL-C patients with AF.

作者陈颖黄青黄波水梁坚林梁发胜周淑娴

机构地区中山大学孙逸仙纪念医院心内科深圳市福永人民医院心内科

出处《岭南急诊医学杂志》 2015年第5期364-365,368,共3页 Lingnan Journal of Emergency Medicine

基金广东省科技计划项目(2013B021800109)

关键词心房颤动炎症反应他汀类药物 hs-CRP atrial fibrillation inflammation statin therapy hs-CRP

分类号 R541.75 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献9

1Harada M, Van Wagoner DR, Nattel S. Role ofinflammation in atrial fibrillation pathophysiology andmanagement[J]. Circ J,2015,79(3):495.
2Hermida J, Lopez FL, Montes R, et al. Usefulness ofHigh-Sensitivity C-Reactive protein to predict mortalityin patients with atrial fibrillation (from theatherosclerosis risk in communities [ARIC] study) [J].Am J Cardiol, 2012,109( 1 ) :95.
3January CT,Wann LS,Alpert JS,et al. 2014 AHA/ACC/HRS guideline for the management of patientswith atrial fibrillation: Executive summary: A report ofthe american college of Cardiology/American heartassociation task force on practice guidelines and theheart rhythm society [J]. Circulation,2014,130(23):2071.
4Zheng H, Xue S, Hu Z, et al. The use of statins toprevent postoperative atrial fibrillation after coronaryartery bypass grafting : A meta—analysis of 12 studies[J]. J Cardiovasc Pharmacol, 2014,64(3):285.
5Loffredo L, Angelico F, Perri L, et al. Upstreamtherapy with statin and recurrence of atrial fibrillationafter electrical cardioversion. Review of the literatureand meta -analysis [ J ]. BMC Cardiovasc Disord, 2012,12:107.
6Mazurek T,Kiliszek M, Kobylecka M,et al. Relationof proinflammatory activity of epicardial adipose tissueto the occurrence of atrial fibrillation [ J ]. Am JCardiol, 2014,113(9): 1505.
7Psychari SN , Apostolou TS, Sinos L, et al. Relation ofelevated C—reactive protein and interleukin—6 levels toleft atrial size and duration of episodes in patients withatrial fibrillation[ J]. Am J Cardiol, 2005 , 95(6): 764.
8Sonmez 0, Ertem F, Vatankulu M, et al. Novel fibro-inflammation markers in assessing left atrial remodelingin non-valvular atrial fibrillation [J]. Med Sci Monit,2014,20:463.
9Zhang Y, Wang YT, Shan ZL, et al. Role ofinflammation in the initiation and maintenance of atrialfibrillation and the protective effect of atorvastatin in agoat model of aseptic pericarditis [J]. Mol Med Rep ,2015’11(4):2615.